Jefferies Group Analysts Boost Earnings Estimates for Sucampo Pharmaceuticals Inc. (SCMP)
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) – Equities research analysts at Jefferies Group upped their FY2016 earnings estimates for shares of Sucampo Pharmaceuticals in a report issued on Wednesday. Jefferies Group analyst D. Steinberg now forecasts that the brokerage will post earnings of $1.23 per share for the year, up from their previous estimate of $1.02. Jefferies Group currently has a “Hold” rating and a $16.00 target price on the stock. Jefferies Group also issued estimates for Sucampo Pharmaceuticals’ Q4 2016 earnings at $0.50 EPS, FY2017 earnings at $1.66 EPS, FY2018 earnings at $1.78 EPS, FY2019 earnings at $1.90 EPS and FY2020 earnings at $2.30 EPS.
Several other research firms also recently weighed in on SCMP. Maxim Group increased their price target on Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday. Mizuho raised their target price on Sucampo Pharmaceuticals from $13.00 to $16.00 and gave the stock a “neutral” rating in a research note on Monday. Vetr downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 target price for the company. in a research note on Monday, September 19th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 8th. Finally, Northland Securities began coverage on Sucampo Pharmaceuticals in a research note on Wednesday, September 7th. They issued an “outperform” rating and a $15.00 target price for the company. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $17.33.
Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 15.85 on Monday. Sucampo Pharmaceuticals has a 12-month low of $9.59 and a 12-month high of $18.75. The company has a market capitalization of $678.67 million, a PE ratio of 53.55 and a beta of 1.62. The stock’s 50 day moving average price is $12.79 and its 200 day moving average price is $11.84.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.02. The firm earned $57.90 million during the quarter, compared to the consensus estimate of $51.30 million. Sucampo Pharmaceuticals had a return on equity of 44.19% and a net margin of 6.29%. The business’s quarterly revenue was up 73.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.16 earnings per share.
Several hedge funds have recently added to or reduced their stakes in the stock. Zacks Investment Management acquired a new stake in Sucampo Pharmaceuticals during the second quarter valued at $110,000. Boothbay Fund Management LLC acquired a new stake in Sucampo Pharmaceuticals during the first quarter valued at $114,000. Smith Asset Management Group LP boosted its stake in Sucampo Pharmaceuticals by 69.5% in the second quarter. Smith Asset Management Group LP now owns 10,730 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 4,400 shares during the last quarter. Princeton Alpha Management LP acquired a new stake in Sucampo Pharmaceuticals during the second quarter valued at $138,000. Finally, Nine Chapters Capital Management LLC acquired a new stake in Sucampo Pharmaceuticals during the third quarter valued at $142,000. 41.14% of the stock is currently owned by hedge funds and other institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.